Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07007559 · ClinicalTrials.gov registry record · Phase 1
ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies
A Phase 1 study of Breast Cancer Metastatic, sponsored by ALX Oncology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 11
- Study locations
NCT07007559 is a Phase 1 study of Breast Cancer Metastatic that is actively recruiting participants, run by ALX Oncology. The registered enrollment target is 80 participants, roughly in line with the 88-participant average among 17 other Breast Cancer Metastatic trials with a reported enrollment target. The trial reports 11 study locations across 8 states.
The verdict
NCT07007559, a Phase 1 study of Breast Cancer Metastatic, is actively recruiting participants, sponsored by ALX Oncology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to evaluate evorpacept with anti-cancer therapies in advanced/metastatic malignancies. The study is comprised of the following substudies: * Metastatic HER2+ breast cancer (MBC) - single-arm substudy evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic breast cancer who have previously received trastuzumab-deruxtecan. This substudy is actively recruiting. * Metastatic colorectal cancer (CRC) - dose escalation phase to evaluate evorpacept in combination with other drugs. This substudy is not recruiting. * Recurrent/metastatic head and neck cancer (HNSCC) - dose escalation phase to evaluate evorpacept in combination with other drugs. This substudy is not recruiting.
Conditions Studied
Interventions
- DRUG Trastuzumab
- DRUG Capecitabine
- DRUG Paclitaxel
- DRUG Evorpacept (ALX148)
- DRUG Eribulin
Study Locations (11)
Colorado
- Saint Joseph Hospital - Cancer Centers of Colorado - Denver
- Lutheran Hospital - Cancer Centers of Colorado - Golden
- Saint Mary's Regional Hospital - Cancer Centers of Colorado - Grand Junction
Texas
- University of Texas Southwestern Medical Center - Dallas
- The University of Texas M.D. Anderson Cancer Center - Houston
Arizona
- The University of Arizona Cancer Center - North Campus - Tucson
District of Columbia
- The George Washington Medical facility Associates - Washington D.C.
Michigan
- University of Michigan Rogel Cancer Center - Ann Arbor
Minnesota
- HealthPartners Frauenshuh Cancer Center - Saint Louis Park
Nebraska
- Oncology Hematology West, Pc Dba Nebraska Cancer Specialists - Omaha
Ohio
- Gabrail Cancer Center - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-04-28 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07007559
The ClinicalTrials.gov registry entry for NCT07007559 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 88-participant average among 17 other Breast Cancer Metastatic trials with a reported enrollment target. The listed sponsor is ALX Oncology, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer Metastatic appearing as the primary indexed condition, and to 5 interventions - of which Trastuzumab is the first listed.
NCT07007559 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Colorado, Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT07007559 about?
NCT07007559 is a clinical study titled "ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies". The purpose of this study is to evaluate evorpacept with anti-cancer therapies in advanced/metastatic malignancies. The study is comprised of the following substudies: * Metastatic HER2+ breast cancer (MBC) - single-arm substudy evaluating the efficacy, safety, and tolerability of evorpacept in com...
What is the current status of trial NCT07007559?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2025-04-28. Estimated completion is 2027-12.
What conditions does trial NCT07007559 study?
This clinical trial studies the following conditions: Breast Cancer Metastatic.
What interventions are being tested in trial NCT07007559?
The interventions under investigation include: Trastuzumab (DRUG), Capecitabine (DRUG), Paclitaxel (DRUG), Evorpacept (ALX148) (DRUG), Eribulin (DRUG).
Who is sponsoring clinical trial NCT07007559?
This trial is sponsored by ALX Oncology, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07007559 being conducted?
This trial has 11 study locations across Arizona, Colorado, District of Columbia, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer
RECRUITING · Phase 1
-
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
RECRUITING · Phase 1
-
Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy
RECRUITING · Phase 1
-
SLV-154 Treatment of Metastatic Solid Tumors
RECRUITING · Phase 1
-
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.